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Abstract
Background: Community-acquired pneumonia (CAP) is considered the most important cause of death from
infectious disease in developed countries. Severity assessment scores partially address the difficulties in identifying
high-risk patients. A lack of specific and valid pathophysiologic severity markers affect early and effective sepsis
therapy. HMGB-1, sRAGE and RAGE have been involved in sepsis and their potential as severity markers has been
proposed. The aim of this study was to evaluate HMGB-1, RAGE and sRAGE levels in patients with CAP-associated
sepsis and determine their possible association with clinical outcome.
Method: We evaluated 33 patients with CAP-associated sepsis admitted to the emergency room and followed in
the medical wards. Severity assessment scores (CURB-65, PSI, APACHE II, SOFA) and serologic markers (HMGB-1,
RAGE, sRAGE) were evaluated on admission.
Results: Thirty patients with a diagnosis of CAP-associated sepsis were enrolled in the study within 24 hours after
admission. Fourteen (46.6%) had pandemic (H1N1) influenza A virus, 2 (6.6%) had seasonal influenza A and 14
other diagnoses. Of the patients in the study group, 16 (53.3%) had a fatal outcome. ARDS was observed in 17
(56.6%) and a total of 22 patients had severe sepsis on admission (73%). The SOFA score showed the greatest
difference between surviving and non-surviving groups (P = .003) with similar results in ARDS patients (P = .005).
sRAGE levels tended to be higher in non-surviving (P = .058) and ARDS patients (P = .058). Logistic regression
modeling demonstrated that SOFA (P = .013) and sRAGE (P = .05) were the only variables that modified the
probability of a fatal outcome.
Conclusion: The association of elevated sRAGE with a fatal outcome suggests that it may have an independent
causal effect in CAP. SOFA scores were the only clinical factor with the ability to identify surviving and ARDS
patients.
Keywords: SOFA score, Soluble RAGE, Severity markers, Community-acquired pneumonia, Survival
Background
Community-acquired pneumonia (CAP) is considered
the leading cause of death from infectious disease in
developed countries [1]. In Mexico, the annual estimated
incidence is100 to 230 cases per 100, 000 inhabitants,
causing an alarming impact on public health since 25% of
these cases require hospitalization [2]. Severity assess-
ment scores help identify high-risk patients that need
hospital therapy; however, the lack of specific and valid
pathophysiologic severity markers affects early effective
interventions. The recent H1N1 influenza pandemic
(p2009A H1N1 or S-OIV) was associated with an
increase in cases of CAP that required hospitalization
and continues to be a national public health threat [3-6].
Although the mortality rate was only 1.8%, 31% of
patients with severe disease were admitted to an intensive
care unit, and 14%-46% died [7-10]. The first 18 cases,
seen from March 24 to April 24, 2009 were reported at
the National Institute of Respiratory Diseases in Mexico
City. More than half of the patients were between 13 and
47 years of age. Twelve patients required mechanical ven-
tilation and seven died (38%) [3]. Increased mortality was
associated with systemic manifestations and
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complications of CAP with sepsis being the most com-
mon and challenging.
Physicians may underestimate the severity of CAP,
which can lead to insufficiently aggressive interventions
inpatients with a high risk of complications [11,12]. Scor-
ing systems have been used to calculate the probability of
morbidity or mortality. The most studied scoring system,
the Pneumonia Severity Index (PSI), is a 20-point score
that classifies patients into five risk categories based on
their percentage of risk of death within 30 days. This score
was useful in patients with a low risk of death (0.1%-0.7%)
and was recommended for outpatient therapy [13]. How-
ever, PSI is limited by its number of variables, making it
complex for the emergency room setting [14].
The British Thoracic Society subsequently designed a
simpler prediction tool, the confusion, urea, respiration,
and blood pressure (CURB) score, also based on the risk
of 30 day mortality [12]. In 2003, Lim and colleagues
added age ≥65 years as a risk factor to create CURB-65
[15]. CURB-65 is significantly easier to use than PSI since
it has only five variables with a single point awarded for
each. CURB-65 is recommended together with PSI.
Other severity assessments, such as the Acute Physiol-
ogy and Chronic Health Evaluation II (APACHE II), are
commonly used in intensive care units to determine a
patient’s outcome. The Sequential Organ Failure Assess-
ment score (SOFA) on admission has also been used
with results similar to APACHE II. The combination of
these may improve sensitivity [16].
Current severity assessment scores only partially over-
come the difficulties in identifying patients with severe dis-
ease, providing objective classifications of patients into
high-risk categories [17]. Thus, there is increasing interest
in improving diagnostic accuracy by measuring inflamma-
tory mediators that participate in sepsis. In 1999, Wang
et al. reported that high-mobility group box 1 (HMGB1)
was detectable in plasma of mice exposed to a lipopolysac-
charide. Removal of circulating HMGB1 with a specific
antibody improved survival. HMGB1 has delayed kinetics
and remains in circulation longer than the initial studied
immunologic mediators. HMGB-1 induces the release of
proinflammatory and procoagulant factors and when
injected into mice, leads to the development of clinical fea-
tures of sepsis and multiorgan dysfunction [18].
Angus and colleagues studied serum HMGB1 levels in a
subgroup of 122 patients with CAP and observed elevated
levels more than a week after presentation with high circu-
lating levels associated with greater mortality [19]. These
data differ from Sunden-Cullberg et al., who found lower
HMGB1 serum levels in non-survivors of severe sepsis
[20]. There have also been studies evaluating the role of
HMGB-1’s receptor, the receptor for advanced glycation
end products (RAGE) [21]. Experimental studies demon-
strate that RAGE-dependent activation of nuclear factor-
kappa B (NF-B) plays a central role in modulating mor-
tality after cecal ligation and puncture [22]. RAGE pos-
sesses a secretory isoform known as soluble RAGE
(sRAGE), which maintains the extracellular ligand-binding
domain but lacks the cytosolic and transmembrane
domains. sRAGE has the same ligand binding specificity
and competes with cell-bound RAGE, serving as a decoy
that abolishes cell activation. In sepsis models, the admin-
istration of exogenous sRAGE slightly improved survival
[22]. Evidence suggests that human endogenous sRAGE is
generated by alternative splicing of RAGE mRNA, or alter-
natively, by proteolytic cleavage from membranous RAGE
[23]. This former mechanism was considered to be a cell
regulating mechanism, permitting restoration of homeos-
tasis and survival.
Since there is very little knowledge of the role of
HMGB-1/RAGE in the clinical setting of CAP-associated
sepsis, we decided to perform a pilot study to investigate
of HMGB-1, RAGE and sRAGE levels in septic patients
with CAP and identify if there is a correlation with severity
assessment scores.
Methods
Study groups
This observational clinical study included patients evalu-
ated at the UANL University Hospital in Monterrey, Mex-
ico. The Bioethics Committee of the School of Medicine
of the Universidad Autonoma de Nuevo Leon previously
approved this project and written informed consent was
obtained from the patient or a legal representative. Thirty-
three consecutive patients, from July 2009 through August
2010, were enrolled in the study within the first 24 hours
of their arrival to the emergency room with sepsis second-
ary to CAP. They were followed-up either in the general
ward or in the intensive care unit. Patients were classified
according to the Sepsis Consensus Conference of 1992
[24] and the Infectious Diseases Society of America. Clini-
cal data, diagnosis, treatment modalities, and blood sam-
ples were collected.
The severity of CAP was estimated using the following
scores: CURB-65, PSI, APACHE II, and SOFA. To be
enrolled, subjects had to be ≥ 18 yrs of age and have both
a clinical diagnosis of pneumonia and a new pulmonary
infiltrate on chest X-ray. Patients with hospital-acquired
pneumonia, an episode of pneumonia in the last 30 days,
pulmonary tuberculosis, pregnancy, palliative care, cancer,
human immunodeficiency virus infection, chronic steroid
use, acute or chronic viral liver disease, and chronic renal
disorders were excluded from the study.
At enrollment, blood samples were taken, and RAGE
receptor was immediately detected by flow cytometry,
determining its mean fluorescence intensity. Subsequently
HMGB-1 and sRAGE antigen were determined in plasma
by enzyme-linked immunosorbent assay (ELISA). At the
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same time, CURB-65, PSI, APACHE II score, and SOFA
score were documented. During the patient’s hospital stay
we evaluated the presence of acute respiratory distress
syndrome (ARDS). Also, a follow-up at 28 days was per-
formed to distinguish between survivors and non-survi-
vors. After enrollment of patients, data was blinded to
avoid potential bias.
HMGB1 and soluble RAGE assay
Blood samples were obtained from each patient and sera
were recovered to test HMGB1 and soluble RAGE
levels. The HMGB1 ELISA kit (IBL International, Ger-
many) and the soluble RAGE ELISA kit (R&D system,
Minneapolis, Mn) were used according to the manufac-
turer’s recommendations.
Membrane RAGE assay
A sample of whole blood, anticoagulated with EDTA, from
each patient was used for flow cytometry analysis. One
hundred microliters of whole blood was incubated with a
rabbit anti-human RAGE antibody (Chemicon, Billerica,
MA) for 15 min at room temperature. A Goat anti-Rabbit
IgG FITC conjugate (Chemicon) was used for flow cyto-
metry detection. Samples were incubated for 15 min at
room temperature in darkness. Lysis solution was then
added to eliminate erythrocytes and two washes with PBS
(0.1 M, pH 7.2) were done centrifuging at 220-240 × g
for10 min in each time. Leukocytes were recovered by
centrifugation in the same condition and the samples were
resuspended in 1 ml of FACS flow (BD Biosciences, Phar-
mingen) for cytofluorometric analysis (FACS SortCalibur,
BD, San Jose, CA). Then 10, 000 cells, in which mean
fluorescence intensity (MFI) was obtained and nonspecific
fluorescence was deleted, were analyzed.
Statistical analysis
All statistical analyses were performed in SPSS (SPSS, ver-
sion 13.0), assuming a statistical significance of P ≤ .05.
The general descriptive characteristics are presented as
means, standard deviations, medians, and percentages. We
compared the severity assessment scores and HMGB-1,
RAGE and sRAGE levels in surviving and non-surviving
patients at 28 days, and between ARDS and non-ARDS
patients using a statistical inferential analysis with the U
Mann-Whitney nonparametric test. Using the normality
tests Kolmogorov-Smirnov with the Lilliefors correction
and Shapiro-Wilk, we determined if the obtained values
came from a normally distributed population. We present
data as plots of admission day medians.
We used multivariate logistic regression and Cox
regression models with a backward technique to select
variables that predicted a fatal outcome, including clinical
severity and the inflammatory markers studied, such as
age, gender, CURB-65, SOFA score, APACHE II,
pneumonia severity index, HMGB-1, sRAGE and RAGE.
Correlation between clinical severity scores and immuno-
logic markers at admission, and between the markers,
was detected using Spearman’s correlation coefficient.
Acute organ dysfunction was defined as a new
Sequential Organ Failure Assessment score [25] ≥3 in
any of six organ systems, following the European Society
of Intensive Care Medicine sepsis occurrence in the
acutely ill patient study criteria [26]. We also added
patients that met the following alternate definition to
the analyses: an increase of 1 Sequential Organ Failure
Assessment point in any two organ systems, 2 points in
one system, or an absolute score of ≥3 in the respiratory
system, similar to criteria used in several large trials of
antisepsis agents [27-29].
Results
Study population
Thirty-three patients with confirmed CAP were included
in the study; three were excluded (one was pregnant and
two because of problems with their blood sample). Of the
remaining 30 patients, 14 (46.6%) had pandemic (H1N1)
2009 influenza virus confirmed by PCR and 2 patients
(6.9%) had seasonal influenza A. No etiologic agent was
found in the other 14 patients. Twenty-two patients
(73.3%) had severe sepsis or septic shock detected at
admission; of these, 17 developed acute respiratory dis-
tress syndrome (ARDS). The mortality rate of the study
group was a total of 16 patients (53.3%) at the end of the
28 days. There were eight who never developed severe
sepsis and survived to hospital discharge, six who devel-
oped severe sepsis and survived to discharge, and 16 who
developed severe sepsis and died in the hospital.
There were no significant differences between survival
and non-survival patients with respect to age, gender,
ethnicity, microbiological etiology, initial CURB-65,
initial PSI class, initial APACHE II score, or emergency
room length of stay (P value range, .07-.99) nor between
ARDS and non-ARDS patients with respect to gender,
ethnicity, microbiological etiology, initial CURB-65,
initial PSI class, initial APACHE II score, or emergency
room length of stay (P value range, .36-.77) (Figure 1A).
Group characteristics are provided in Table 1. Compared
with those who did not survive, those who survived had
lower SOFA scores (5.5, CI: 4.9-7.7 versus 3, CI: 2.3-4.2)
(Figure 1B). Compared with patients that did not develop
ARDS, those with ARDS had higher SOFA scores (3, CI:
2.1-4.9 versus 5, CI: 4.6-7.1) and were younger (Figure 2B
and Table 1).
There were no statistically different RAGE, sRAGE
and HMGB-1 levels found during early CAP-associated
sepsis in ARDS or non-surviving patients (Figure 1C,
Figure 1E, Figure 2A and Table 2). No difference was
found between influenza A H1N1 infected patients and
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the rest of the study group (2767 ± 1655 vs 2174 ±
1344, P = .327). We did not find a correlation between
immunological molecules and severity assessment scores
using Spearman’s correlation coefficient (P value range =
.16-.99). Finally, none of the studied severity assessment
scores correlated with each other (P value range =
.18-.79).
Logistic regression model
Using a logistic regression model involving age, gender,
APACHE II, SOFA, HMGB-1, sRAGE and RAGE, we
found that the only variables that modified the probabil-
ity of the patient having a fatal outcome were SOFA
(P = .013) with a relative risk of surviving of .347 (CI:
.151-.797); and sRAGE (P = .05) with a relative risk of
surviving of .998 (CI: .998-1) (Table 3).
Cox regression model
According to multivariate Cox regression analysis we
found that a high SOFA score was an independent pre-
dictor of non-survival (hazard ratio 1.53, CI: 1.2-1.97,
P = .001) (Table 4).
Discussion
We found that SOFA scores and the measurement of
sRAGE levels in patients with CAP-associated sepsis
helped predict survival. To date, this is the first study
that analyses the levels of both of these molecules (the
“HMGB-1” ligand and the “RAGE” receptor) in the
inflammatory cascade of patients with CAP-associated
sepsis. In Mexico, as in developed countries, CAP con-
tinues to be an important cause of death from infectious
disease [1] with an elevated cost to public health. This
was particularly evident with the H1N1 (2009, S-OIV)
influenza virus pandemic [8]. Overall mortality is about
50% in patients with CAP that develop septic shock
[25]. Although there has been intense research on the
pathophysiology of CAP and its severe forms, such as
ARDS, only slight improvements in new and effective
treatment strategies have occurred.
Despite the identification of several recent molecules
in patients with infection, such as the receptor expressed
on myeloid cells-1 (TREM-1), these lack specificity in
sepsis pathophysiology [26-28]. Discovery of markers
may add additional information, increasing the validity
A)                                        B)                                       C) 
D)                                        E)                                        
Figure 1 Analysis of CURB-65 score, SOFA score, soluble RAGE, membrane RAGE and HMGB-1 levels in survival and non-survival
patients. A) CURB-65 and B) SOFA scores were obtained using international protocols. C) Serological soluble RAGE and D) HMGB-1 levels were
measured by ELISA. E) Membrane RAGE levels were analyzed by flow cytometry. Data represent the median and were analyzed using Mann
Whitney U test.
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of clinical estimates and permitting early, aggressive, and
effective sepsis therapy. This justifies every effort to
further explore the paradigm of biomarkers in the area
of pulmonary infections [29]. We still lack efficient tools
to identify patients with CAP who are likely to develop
severe complications. Current clinical severity scores
partially limit these difficulties, but are far from perfect.
In our study, CURB-65, APACHE II and PSI
Table 1 Characteristics of the patients in comparative groups: surviving vs non-surviving, ARDS vs non-ARDS
Characteristics ARDS
(n = 17)
Non-ARDS
(n = 13)
P
value
Non-Surviving
(n = 16)
Surviving
(n = 14)
P
value
Age, mean (SD) 35.8 (11) 54 (20) 38 (14) 50 (21)
Male sexa 9 (53) 4 (31) 10 (62.5) 3 (21)
CURB-65 2 (1.45-2.20) 1 (0.89-2.34) .48 2 (1.49-2.51) 1 (0.94-1.92) .076
PSI class 3 (2.72-3.98) 2 (2.15-3.85) .45 4 (2.72-4.28) 2.5 (2.26-3.45) .224
APACHE II
score
11 (10.18-15) 12 (7.54-13.39) .36 11.5 (9.66 - 15.47) 11.5 (8.42-12.87) .400
SOFA score 5
(4.69-7.19)
3
(2.11-4.97)
.003 5.5
(4.91-7.71)
3
(2.37-4.20)
.001
Mortalitya 13 (76) 3 (23) ———————————— ————————————
Renal failurea 2 (11) 0 (0) 2 (12) 0 (0)
Shocka 4 (23) 2 (15) 6 (37) 0 (0)
Respiratory
failurea
—————————— ——————————— 13 (81) 4 (28.5)
Microbiological
etiology, n (%)
H1N1 S-OIV
2009a
10 (59) 4 (31) 8 (50) 6 (43)
Seasonal
Influenzaa
2 (12) 0 (0) 2 (12.5) 0 (0)
Othersa 5 (29) 9 (69) 6 (37.5) 8 (57)
APACHE, Acute Physiology and Chronic Health Evaluation; SOFA, Sepsis-Related Organ Failure Assessment; S-OIV, swine origin influenza virus
aDefined according to the 1992 American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference guidelines(16). Data are mean (SD),
median (CI), or n (%) when appropriate
A)                                                             B) 
Figure 2 Analysis of soluble RAGE and SOFA score in ARDS and non-ARDS patients. Data represent the median and were analyzed using
Mann Whitney U test.
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demonstrated no difference between groups (fatal out-
come and ARDS). Recently published studies have
found that CURB-65 dose not reliably distinguish
patients with pandemic influenza CAP who will have
good or poor outcomes [30,31]. In the case of PSI, this
could represent its higher ability to detect mild cases;
although, this could be explained by the small number
of patients in our study. In contrast, we noticed that
SOFA scores, although not specific for CAP, were signif-
icantly higher in non-surviving or ARDS patients. Thus,
in spite of the wide variety of etiologies, this last organ
dysfunction score seems to be useful in patients with
CAP.
It is well known that the recognition receptor “RAGE”
and HMGB-1 play a central role in the innate immune
system with an impact on its perpetuation and amplifica-
tion [22]. RAGE stimulation results in sustained NF-B
activation, which may be a predictor of severity in sepsis
[32]. Conditions that induce NF-B also increase RAGE
expression, which in turn produces sustained inflamma-
tion; this is seen in CAP, where RAGE ligands are abun-
dantly present. Angus et al. found that CAP patients had
higher HMGB-1 concentrations, and this correlated with
mortality [19]. Gaini et al. also found higher levels of
HMGB-1 in CAP [33]. Studies of severe influenza CAP
demonstrated an association between excessive release of
cytokines and increased mortality [34,35]. However,
Alleva et al. found in a murine model of severe influenza
that HMGB-1 concentrations were not increased in
plasma at the time of peak mortality, and peak levels of
HMGB1 did not occur until relatively late in infection
[36].
Recently, Bopp et al. demonstrated that sRAGE concen-
trations in sepsis patients were higher in non-survivors
when compared with survivors. They concluded that
larger clinical trials should study the potential role of
sRAGE as a new sepsis marker [37]. However, sRAGE has
been used in animal models to block HMGB-1’s binding
to the RAGE receptor, leading to increased survival. This
data indicates that HMGB-1 and RAGE participate in sep-
sis, including sepsis patients with CAP.
After developing multivariate regression models using
backward selection techniques, we found that sRAGE and
SOFA predicted survival; although the statistical signifi-
cance was greater for SOFA, a limitation of our study is
the small number of patients. One explanation for the ele-
vated sRAGE levels could be an increased gene expression
of RAGE in patients with sepsis [22,38]. Since we know
that RAGE participates in tissue damage [39], it could
represent a marker for cellular damage in sepsis.
As mentioned previously, there were elevated concentra-
tions of sRAGE on admission in those with a fatal out-
come, but without statistical significance. The same was
observed in those patients who developed ARDS. On the
other hand, receptor RAGE and HMGB-1 demonstrated
lower differences between groups. Larger studies will be
necessary to investigate the role of these potential sepsis
markers.
The elevated levels of sRAGE found in our study, as in
others, might represent the septic status of the patients as
splice-variants of RAGE or shed variants of cell surface
RAGE. In contrast to animal studies where a protective
effect of sRAGE was seen, we found that sRAGE levels
were higher in patients with more inflammation and in
non-survivors. This finding could be related to shed var-
iants of cell surface RAGE but this aspect was not one of
our objectives. The ELISA we used did not differentiate
between splicing variants and the shed variants of RAGE.
To the best of our knowledge, this is the second study
that finds higher sRAGE levels in plasma of sepsis non-
survivors compared with survivors [37]. This has
Table 2 Immunologic marker levels in comparative groups: surviving vs. non-surviving, ARDS vs. non-ARDS
Non-Surviving Patients
[total n = 16] (CI)
Surviving Patients
[total n = 14] (CI)
P value Non-ARDS Patients
[total n = 13] (CI)
ARDS Patients
[total n = 17] (CI)
P value
HMGB-1 (ng/mL)a 11.76 [13] (-5.65-60) 6.78 [12] (4.5-17.66) .44 10.11 [11] (4.64-18.97) 11.11 [14] (-4.83-55.51) .64
RAGE (MFI)a 88.88 [15] (55.9-150.8) 116.7 [14] (51.9-456.2) .21 98.01 [12] (6.68-492.31) 90.63 [17] (75.55-173.27) .94
sRAGE (pg/mL)a 3236 [15] (2312-3673) 1037 [13] (912.8-2769) .058 1829.75 [13] (1079-2629) 3296 [15] (2168-3793) .058
HMGB-1, high mobility group box -1, RAGE, receptor for advanced glycation end products; sRAGE, soluble RAGE; MFI, mean fluorescence intensity
[n] Expresses the numeral of results analyzed, from the total number
aData is expressed as median (CI)
Table 3 Logistic Regression Model analysis
Sig. Exp(B) 95% C.I. Exp(B)
sRAGE .050 .999 .998 1.000
SOFA score .013 .347 .151 .797
Constant .010 2721.943
Variables included in equation: RAGE, sRAGE, HMGB-1, SOFA score, APACHE II
score, gender, age
Table 4 Cox Regression Model analysis
Sig. Exp(B) 95% C.I. Exp(B)
sRAGE .050 .999 .998 1.000
SOFA score .013 .347 .151 .797
Variables included in equation: RAGE, sRAGE, HMGB-1, SOFA score, APACHE II
score, gender, age
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discrepancies with mouse model studies of sepsis after
CLP [22]. This could be in part explained by different
kinds of sepsis, different etiologic agents, and what was
difficult to determine in our study, the time of measure-
ment after the immunologic process started.
We do not know if sRAGE concentrations were
enough to bind HMGB-1, after they had scavenged
AGEs and other RAGE ligands. Moreover, the higher
concentrations found in sicker patients could represent
sRAGE modified structurally and functionally during
sepsis, diminishing its binding and neutralizing capacity.
Conclusions
Plasma sRAGE levels are elevated in CAP patients.
sRAGE performed as an independent factor affecting
the probability of a fatal outcome. Interestingly, the
SOFA score demonstrated greater accuracy with the
ability to differentiate between surviving/non-surviving
and ARDS/non-ARDS groups.
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